Axis Capital Holdings Ltd. (AXS)
NYSE NYSE Primary 
XFRA 
Axis Capital (AXS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Axis Capital (AXS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axis Capital (AXS) Q4 Earnings Beat Estimates
Axis Capital (AXS) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.68 per share. This compares to earnings of $2.94 per share a year ago.
Why Axis Capital (AXS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Axis Capital (AXS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Earnings Preview: Axis Capital (AXS) Q4 Earnings Expected to Decline
Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXS Rallies 58.5% in a Year: A Signal for Investors to Hold Tight?
AXIS Capital stock rallies on the back of well-performing specialty insurance, reinsurance as well as the accident and health portfolio.
Will Axis Capital (AXS) Beat Estimates Again in Its Next Earnings Report?
Axis Capital (AXS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, supporting a bullish outlook.
Here's Why Axis Capital (AXS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 P&C Insurance Stocks That Have Gained More Than 50% in 2024
Despite higher catastrophe losses, MCY, AXS and PLMR not only outperforms the industry but also crushes the Zacks S&P 500 composite and the Finance sector.
AXIS Capital: A Niche Leader Priced For NOPAT Fall
AXIS Capital is a global leader in specialty insurance and reinsurance, with a 30.2% annual NOPAT growth and a 15.3% ROIC in TTM. The company's diversified portfolio, disciplined risk management, and innovation focus position it to continue delivering value despite market challenges. AXIS's market valuation implies a 31% decline in future NOPAT, presenting a compelling investment opportunity given its strong historical performance.
Why Axis Capital (AXS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
